 |
|
Thinking the pain away? Study shows the brain's painkillers may cause 'placebo effect'
August 24, 2005Sham painkiller prompts brain to release endorphins, bringing real relief to those in pain
ANN ARBOR, Mich. - Just thinking that a medicine will relieve pain is enough to prompt the brain to release its own natural painkillers, and soothe painful sensations, a new University of Michigan study finds.
The study provides the first direct evidence that the brain's own pain-fighting chemicals, called endorphins, play a role in the phenomenon known as the placebo effect - and that this response corresponds with a reduction in feelings of pain.
Previous studies at U-M and elsewhere have shown that the brain reacts physically when a person is given a sham pain treatment, which they believe will help them.
But the new study is the first to pinpoint a specific brain chemistry mechanism for a pain-related placebo effect. It may help explain why so many people say they get relief from therapies and remedies with no actual physical benefit. And, it may lead to better use of cognitive, or psychological, therapy for people with chronic pain.
The results will be published in the August 24 issue of the Journal of Neuroscience by a team from the U-M Molecular and Behavioral Neurosciences Institute (MBNI). The research was funded by the National Institutes of Health.
"This deals another serious blow to the idea that the placebo effect is a purely psychological, not physical, phenomenon," says lead author Jon-Kar Zubieta, M.D., Ph.D., associate professor of psychiatry and radiology at the U-M Medical School and associate research scientist at MBNI. "We were able to see that the endorphin system was activated in pain-related areas of the brain, and that activity increased when someone was told they were receiving a medicine to ease their pain. They then reported feeling less pain. The mind-body connection is quite clear."
The findings are based on sophisticated brain scans from 14 young healthy men who agreed to allow researchers to inject their jaw muscles with a concentrated salt water solution to cause pain. The injection was made while they were having their brains scanned by a positron emission tomography (PET) scanner. During one scan, they were told they would receive a medicine (in fact, a placebo) that might relieve pain.
Every 15 seconds during the scans, they were asked to rate the intensity of their pain sensations on a scale of 0 to 100, and they gave more detailed first-person ratings after the experiment. The researchers correlated the participants' ratings with their PET scan images, which were made using a technique that reveals the activity of the brain's natural painkilling endorphin chemicals, also called endogenous opioids.
Endogenous opioids bind to brain cell receptors called mu-opioid receptors, and stop the transmission of pain signals from one nerve cell to the next. Besides the brain's own chemicals, drugs such as heroin, morphine, methadone and anesthetics also act on the mu opioid receptor system to reduce pain.
Because the endorphin system naturally tries to quell pain whenever it occurs, the researchers slowly increased the amount of concentrated salt water being injected in the muscle as the scans continued, in order to keep the participants' rating of their pain within the same point range throughout the experiment. The placebo, a small amount of hydrating solution, was then given intravenously every four minutes.
As the researchers alerted participants that the placebo was coming, and injected the placebo dose, the amount of additional concentrated salt water needed to maintain participants' pain over time increased - indicating a reduction in pain sensitivity that the subjects were not aware of. In other words, thinking they were getting a pain drug actually allowed the participants to tolerate even more pain-inducing concentrated salt water than before.
After each scan, the researchers asked the participants more questions about their mood, emotions and other aspects of how they felt during the scans. There were significant differences between post-scan ratings given by participants after the scan in which they received the placebo, and after the scan during which they received the jaw injection alone.
Nine of the participants were classified as "high placebo responders" because they had more than a 20 percent difference between pain and placebo scans in their average pain ratings per volume of salt water infused - in other words, the placebo effect was strong. The other five were classified as "low placebo responders."
These subjective ratings are consistent with previous findings, Zubieta notes. But the simultaneous imaging of the participants' endogenous pain-reducing opioid systems sheds new light on why the placebo effect occurs.
The imaging method used in the study involves tiny doses of a medicine called carfentanil that is attached to a short-lived radioactive form of carbon, which releases subatomic particles known as positrons. These positrons are detected with the PET scanner, which acts like a photographic camera to capture those particles. It then determines exactly which part of the brain they originated from, and how many of them are coming from each brain region. The researchers also made MRI scans of the participants' brains, which they cross-registered with the PET scans to give accurate information on exactly which brain regions were active.
Because carfentanil competes with the brain's natural endogenous opioid painkillers for space on nerve cell receptors, the PET scans can be used to see how active the opioid system and mu-opioid receptors are. The stronger the positron signal from a particular brain region, the less active the mu opioid system, and vice versa.
All of the participants showed an increase in the activation of their mu opioid endorphin system after they were told that the "medicine" was coming and the placebo was given. The most pronounced differences were seen in four areas of the brain known to be involved in complex responses to, and processing of, pain: the left dorsolateral prefrontal cortex, the pregenual rostral right anterior cingulate, the right anterior insular cortex and the left nucleus accumbens.
When the researchers correlated the mu opioid activity changes with the participants' own ratings of their pain and emotions, they also observed that the placebo-induced activation of the opioid system was correlated with various elements of the experience of pain.
For example, activity in the dorsolateral prefrontal cortex was associated with the expectation of pain relief reported by the volunteers. In other areas, that activation was associated with relief of the intensity of pain, how unpleasant it was, or even how the individuals felt emotionally during the pain experience.
Because the new study was done only in healthy men between the ages of 20 and 30, further research will be needed to determine whether the effect occurs in women and in people with various illnesses. The power of placebos to ease pain symptoms has been well-documented in many groups of subjects and illnesses, but the researchers started with healthy young males to rule out the impact of chronic pain, mood disorders and hormone variations, which can also affect the endorphin system.
In addition to Zubieta, the research team included MBNI members Joshua Bueller, Lisa Jackson, David Scott and Janyun Xu; radiology professor Robert Koeppe, Ph.D.; Thomas Nichols, Ph.D., an assistant professor of biostatistics in the U-M School of Public Health; and Christian Stohler, formerly of the U-M School of Dentistry and now at the University of Maryland School of Dentistry.
University of Michigan Health System
Previous studies at U-M and elsewhere have shown that the brain reacts physically when a person is given a sham pain treatment, which they believe will help them.
But the new study is the first to pinpoint a specific brain chemistry mechanism for a pain-related placebo effect. It may help explain why so many people say they get relief from therapies and remedies with no actual physical benefit. And, it may lead to better use of cognitive, or psychological, therapy for people with chronic pain.
The results will be published in the August 24 issue of the Journal of Neuroscience by a team from the U-M Molecular and Behavioral Neurosciences Institute (MBNI). The research was funded by the National Institutes of Health.
"This deals another serious blow to the idea that the placebo effect is a purely psychological, not physical, phenomenon," says lead author Jon-Kar Zubieta, M.D., Ph.D., associate professor of psychiatry and radiology at the U-M Medical School and associate research scientist at MBNI. "We were able to see that the endorphin system was activated in pain-related areas of the brain, and that activity increased when someone was told they were receiving a medicine to ease their pain. They then reported feeling less pain. The mind-body connection is quite clear."
The findings are based on sophisticated brain scans from 14 young healthy men who agreed to allow researchers to inject their jaw muscles with a concentrated salt water solution to cause pain. The injection was made while they were having their brains scanned by a positron emission tomography (PET) scanner. During one scan, they were told they would receive a medicine (in fact, a placebo) that might relieve pain.
Every 15 seconds during the scans, they were asked to rate the intensity of their pain sensations on a scale of 0 to 100, and they gave more detailed first-person ratings after the experiment. The researchers correlated the participants' ratings with their PET scan images, which were made using a technique that reveals the activity of the brain's natural painkilling endorphin chemicals, also called endogenous opioids.
Endogenous opioids bind to brain cell receptors called mu-opioid receptors, and stop the transmission of pain signals from one nerve cell to the next. Besides the brain's own chemicals, drugs such as heroin, morphine, methadone and anesthetics also act on the mu opioid receptor system to reduce pain.
Because the endorphin system naturally tries to quell pain whenever it occurs, the researchers slowly increased the amount of concentrated salt water being injected in the muscle as the scans continued, in order to keep the participants' rating of their pain within the same point range throughout the experiment. The placebo, a small amount of hydrating solution, was then given intravenously every four minutes.
As the researchers alerted participants that the placebo was coming, and injected the placebo dose, the amount of additional concentrated salt water needed to maintain participants' pain over time increased - indicating a reduction in pain sensitivity that the subjects were not aware of. In other words, thinking they were getting a pain drug actually allowed the participants to tolerate even more pain-inducing concentrated salt water than before.
After each scan, the researchers asked the participants more questions about their mood, emotions and other aspects of how they felt during the scans. There were significant differences between post-scan ratings given by participants after the scan in which they received the placebo, and after the scan during which they received the jaw injection alone.
Nine of the participants were classified as "high placebo responders" because they had more than a 20 percent difference between pain and placebo scans in their average pain ratings per volume of salt water infused - in other words, the placebo effect was strong. The other five were classified as "low placebo responders."
These subjective ratings are consistent with previous findings, Zubieta notes. But the simultaneous imaging of the participants' endogenous pain-reducing opioid systems sheds new light on why the placebo effect occurs.
The imaging method used in the study involves tiny doses of a medicine called carfentanil that is attached to a short-lived radioactive form of carbon, which releases subatomic particles known as positrons. These positrons are detected with the PET scanner, which acts like a photographic camera to capture those particles. It then determines exactly which part of the brain they originated from, and how many of them are coming from each brain region. The researchers also made MRI scans of the participants' brains, which they cross-registered with the PET scans to give accurate information on exactly which brain regions were active.
Because carfentanil competes with the brain's natural endogenous opioid painkillers for space on nerve cell receptors, the PET scans can be used to see how active the opioid system and mu-opioid receptors are. The stronger the positron signal from a particular brain region, the less active the mu opioid system, and vice versa.
All of the participants showed an increase in the activation of their mu opioid endorphin system after they were told that the "medicine" was coming and the placebo was given. The most pronounced differences were seen in four areas of the brain known to be involved in complex responses to, and processing of, pain: the left dorsolateral prefrontal cortex, the pregenual rostral right anterior cingulate, the right anterior insular cortex and the left nucleus accumbens.
When the researchers correlated the mu opioid activity changes with the participants' own ratings of their pain and emotions, they also observed that the placebo-induced activation of the opioid system was correlated with various elements of the experience of pain.
For example, activity in the dorsolateral prefrontal cortex was associated with the expectation of pain relief reported by the volunteers. In other areas, that activation was associated with relief of the intensity of pain, how unpleasant it was, or even how the individuals felt emotionally during the pain experience.
Because the new study was done only in healthy men between the ages of 20 and 30, further research will be needed to determine whether the effect occurs in women and in people with various illnesses. The power of placebos to ease pain symptoms has been well-documented in many groups of subjects and illnesses, but the researchers started with healthy young males to rule out the impact of chronic pain, mood disorders and hormone variations, which can also affect the endorphin system.
In addition to Zubieta, the research team included MBNI members Joshua Bueller, Lisa Jackson, David Scott and Janyun Xu; radiology professor Robert Koeppe, Ph.D.; Thomas Nichols, Ph.D., an assistant professor of biostatistics in the U-M School of Public Health; and Christian Stohler, formerly of the U-M School of Dentistry and now at the University of Maryland School of Dentistry.
University of Michigan Health System
Placebo Current Events and Placebo News RSSSteroid Treatment Offers No Benefit In Preemies, Hopkins Children's Study Suggests
Results of a multicenter study led by Johns Hopkins Children's Center challenge the longstanding practice of treating premature babies with hydrocortisone, a steroid believed to fight inflammation and prevent lung disease.
Nerve stimulation therapy alleviates pain for chronic headache
A novel therapy using a miniature nerve stimulator instead of medication for the treatment of profoundly disabling headache disorders improved the experience of pain by 80-95 percent, according to a new study from the University of California, San Francisco and the National Hospital for Neurology and Neurosurgery in London.
Tamoxifen chemoprevention tied to early detection of breast cancer
The drug tamoxifen does not prevent or treat estrogen receptor (ER) negative breast cancer, but it can make the disease easier to find, researchers report in the Oct. 1 Journal of the National Cancer Institute.
Takeda's investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
Combined results from two Phase 3 studies presented at the American College of Gastroenterology Annual Scientific Meeting (ACG) in Orlando, Fla., demonstrated that TAK-390MR resulted in higher healing rates than lansoprazole among patients with more severe grades of erosive esophagitis (EE).
New studies examine the effectiveness of probiotics in IBS
Several studies presented at the American College of Gastroenterology's 73rd Annual Scientific Meeting in Orlando highlight the safety and efficacy of probiotics in improving symptoms and normalizing bowel movement frequency in patients suffering from constipation or diarrhea related to Irritable Bowel Syndrome (IBS).
Genes influence effectiveness of weight-loss drug
Obese patients with a specific genetic make-up lose more weight when taking the weight loss drug sibutramine and undergoing behavioral therapy compared to those without this genetic make-up, reports a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
HIV drug maraviroc effective for drug-resistant patients
As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death.
Treatment window expanded
Patients can still benefit up to 4.5 hours after a stroke if a drug that dis-solves blood clots in the brain is administered. Thus far, three hours had been considered the useful limit for administering thrombolytic drugs.
Supplements no better than placebo in slowing cartilage loss in knees of osteoarthritis patients
In a two-year multicenter study led by University of Utah doctors, the dietary supplements glucosamine and chondroitin sulfate performed no better than placebo in slowing the rate of cartilage loss in the knees of osteoarthritis patients.
Blood Pressure Drug Combination Reduces Heart Attack Deaths
Thousands of patients with high blood pressure could benefit from changing their drug treatment regimen to reduce their risk of cardiac death.
More Placebo Current Events and Placebo News Articles
 | The Pit Bull Placebo: The Media, Myths and Politics of Canine Aggression by Karen Delise First it was the Bloodhound, sensationalized in the dramatizations of Uncle Tom's Cabin. Then it was the Doberman, symbol of the Nazi menace. Today, it is the Pit bull that is vilified for the depravity of his masters. Today, police chase down fleeing Pit bulls in the street, firing dozens of wild shots in response to media-fed rumors of supernatural Pit bull abilities. Politicians coach and... |
 | The Placebo Response and the Power of Unconscious Healing by Richard Kradin Placebo responses are automatic and unconscious and cannot be predicted based on conscious volition. Instead, they reflect complex interactions between the innate reward system of the nervous system and encoded procedural memories and imaginal fantasies. The placebo response contributes inextricably to virtually all therapeutic effects, varies in potency, and likely exhibits its own pathologies.... |
 | Placebo by Howard O. Pittman Webster's dictionary defines "placebo" as a "medication prescribed more for the mental relief of a patient than for the actual effect on his disorder, or something tending to sooth." The doctors tell us that if we know we are being treated with a placebo, it does not work. In our minds we must think that it is a real medication and has the strength or power to heal. If the patient believes this,... |
 | Placebo: Mind over Matter in Modern Medicine by Dylan Evans Can we really cure ourselves of disease by the power of thought alone? Faith healers and alternative therapists are convinced that we can, but what does science say? Contrary to public perception, orthodox medical opinion is remarkably confident about the healing powers of the mind. For the past fifty years, doctors have been taught that placebos such as sugar pills and water injections can... |
 | The Placebo Chronicles: Strange But True Tales From the Doctors' Lounge by Douglas Md Farrago True Tales of the ridiculous, the silly, and the just plain weird cases doctors face—lampooning the medical bureaucracy that makes practicing medicine and getting medical care such a headache.Doctors have a sick sense of humor. This is the deep, dark, and hilarious secret of the medical profession revealed by the irreverent Dr. Douglas Farrago in his popular satirical magazine, Placebo... |
| Addicted to Placebos: Understanding Science and Society by Ph.D. Alan J. Scott Addicted to Placebos is a thought-provoking book designating science as a mode to elevate our existence and enrich our minds. It is all about the inter-connectedness of science and the human condition. It clearly defines science and its importance to society and critical thinking. It presents science as a way of finding meaning and empowerment. It plies unchartered waters for a physical science... | |
| Meaning, Medicine and the 'Placebo Effect' (Cambridge Studies in Medical Anthropology) by Daniel E. Moerman Traditionally, the effectiveness of medical treatments is attributed to specific elements, such as drugs or surgical procedures. However, many other factors can significantly effect the outcome. Drugs with nationally advertised names can work better than the same drug without the name. Inert drugs (placebos, dummies) often have dramatic effects on some patients and effects can vary greatly among... | |
 | The Placebo Response: How You Can Release the Body's Inner Pharmacy for Better Health by Howard Brody, Daralyn Brody The brain can heal the body: that's the remarkable truth behind the body's placebo response. As one of the nation's foremost authorities on the mysterious connection between mind and body, Dr. Howard Brody introduces a radical new understanding of this phenomenon -- and how it can be used to foster good health. The body, says Brody, has an "inner pharmacy" that the brain taps into, according to... |
 | Understanding the Placebo Effect in Complementary Medicine: Theory, Practice and Research The placebo elicits more passionate debate, scepticism and personal belief than almost any other aspect of medicine. As yet there are no concrete answers - but many challenging observations and powerful effects occur daily in healthcare which need to be examined. This book will stimulate and inform every reader - from the experienced practitioner to the new student - who has ever asked, "What is... |
 | " Placebo " : The Singles for Guitar Tab |
| © 2008 BrightSurf.com |